Localized Prostate Cancer COE

Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt

Details
Ashley Ross, MD, PhD, Alan Dal Pra, MD, and Daniel Spratt, MD, discuss two cases of patients each about 18 months post-prostatectomy with rising PSA, evaluating the timing to radiotherapy and the evidence to intensify with ADT. Biographies: Ashley Ross, MD, Ph.D., Associate Professor, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois Alan Dal Pra, MD, A...

Prostate Cancer Screening and Shared Decision Making in the Veterans Health Administration - Stacy Loeb

Details
In this conversation, Mathew Cooperberg and Stacy Loeb discuss recent advances in prostate cancer screening and shared decision making in the Veterans Health Administration (VA). Dr. Loeb highlights findings from a Journal of the National Cancer Institute publication looking at trends of PSA screening in the VA healthcare system and which found a decline in the use of PSA testing among PSA eligibl...

Validating the Genomic Classifier to Identify Patients With a High Risk of Metastasis Among African American Men With Early Localized Prostate Cancer, VANDAAM Study – Kosj Yamoah

Details
When we think about prostate cancer health disparities, particularly there are two main areas of importance, understanding what the effects are and also figuring out what the implementation strategies could be. In this conversation with Alicia Morgans, Director of Radiation Oncology at the Moffitt Cancer Center, Kosj Yamoah highlights the currently enrolling VANDAAM Study, a prospective study vali...

PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu

Details
M Minhaj Siddiqui joins Matthew Cooperberg to highlight the Patient-Centered Outcomes Research Institute (PCORI) grant awarded to researchers at the University of Maryland School of Medicine (UMSOM). The grant supports the initiative to highlight, to a greater extent, the patient's voice in determining the next course of action to chart in the future of active surveillance in the United States. Mo...

Prostate Cancer Modeling: The CISNET Prostate Group - Ruth Etzioni

Details
Ruth Etzioni, PhD joins Matthew Cooperberg, MD MPH in a discussion about the role and history of prostate cancer modeling based upon PSA. Cancer Intervention and Surveillance Modeling Network (CISNET) is a consortium of NCI-sponsored investigators who use simulation modeling to improve our understanding of cancer control interventions in prevention, screening, and treatment and their effects on po...

The Decipher® Genomic Classifier for Recurrent Prostate Cancer in the NRG/RTOG 9601 Randomized Clinical Trial, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen provide insights into the JAMA Oncology publication titled Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. The management of patients with localized and recurrent prostate cancer is driven predominantly at this point by cli...

Genomics Guide Treatment Decisions in Post Prostatectomy Patients - Ashley Ross

Details
A recent systematic review assessed the clinical utility of the Decipher® genomic classifier. This genomic classifier assesses 22 genes representing multiple oncologic pathways and is independently prognostic of oncologic outcomes. During the 2021 ASCO GU Cancers Symposium, Ashley Ross, MD, PhD, highlighted this review and presented on the use of genomics to guide treatment decisions in post-prost...

A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt

Details
Ashley Ross is joined by Daniel Spratt presenting a European Association of Urology publication on A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer . In a field of rapidly acquiring data, among the challenges that motivated this systematic review was the breadth of papers and data being published. Dr. Spratt and colleagues sought to acquire the most up-to-...

Timing of Radiotherapy After Radical Prostatectomy (RADICALS-RT) Journal Club - Zachary Klaassen and Christopher Wallis

Details
The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the RADICALS-RT trial Lancet Oncology publication looking at the timing of radiotherapy following radical prostatectomy which aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy wit...

The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope

Details
Thomas Hope, MD highlights how he came to study somatostatin receptor-based molecular Imaging for neuroendocrine tumors (NET). He takes us back to 2013, to the World Theranostics Conference at Hopkins, focused on neuroendocrine tumors because at that time there were no prostate theranostics. For this work, they put together a gallium dotatate program, which required the same synthesis module requi...
email news signup